| Purpose | Announcement Date | Ex-Date | Record Date | Dividend Amount | Dividend per Share | Remark |
|---|---|---|---|---|---|---|
| Dividend | 14 May 2026 | 3 Jul 2026 | 3 Jul 2026 | 1 | 50 | Final |
| Recommendation of Final cum Special Dividend Recommended a Final Dividend of Rs. 1.00/- per equity share and a special dividend of Rs. 2.00/- per equity share for the Financial Year ended March 31, 2026 and fixation of record date. The Board of Directors have recommended a final dividend of Rs. 1.00/- (@ 50%) per equity share and a special dividend of Rs. 2.00/- (@ 100%) per equity share having face value of Rs. 2/- (Rupees Two) each fully paid-up for the Financial Year ended March 31, 2026, subject to the approval of the Shareholders of the Company at the ensuing Annual General Meeting | ||||||
| Dividend | 14 May 2026 | 3 Jul 2026 | 3 Jul 2026 | 2 | 100 | Special |
| Recommendation of Final cum Special Dividend Recommended a Final Dividend of Rs. 1.00/- per equity share and a special dividend of Rs. 2.00/- per equity share for the Financial Year ended March 31, 2026 and fixation of record date. The Board of Directors have recommended a final dividend of Rs. 1.00/- (@ 50%) per equity share and a special dividend of Rs. 2.00/- (@ 100%) per equity share having face value of Rs. 2/- (Rupees Two) each fully paid-up for the Financial Year ended March 31, 2026, subject to the approval of the Shareholders of the Company at the ensuing Annual General Meeting | ||||||
The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
